Janelle Valérie, Poliquin Laurent, Lamarre Alain
Laboratoire d'immunovirologie, Institut national de la recherche scientifique, Laval, Québec, Canada.
Med Sci (Paris). 2013 Feb;29(2):175-82. doi: 10.1051/medsci/2013292015. Epub 2013 Feb 28.
Cancer is a complex disease that affects more and more people around the world. Unfortunately, existing treatments are only partially efficient and often induce major side effects. Thus, the use of viruses to selectively kill cancer cells is a new promising therapeutic approach. Recently, VSV has been used in oncolytic virotherapy because of its capacity to preferentially infect most human tumor cells. However, despite the availability of good oncolytic VSV mutants, the large variability of tumor cell types and the multiple ways in which they can evade viral infection suggests that therapeutic combinations of various viruses will be necessary to efficiently treat most cancers. A better understanding of the infection mechanisms and immune system recruitment by oncolytic viruses will be of great value for the development of safe and efficient strategies for cancer treatment.
癌症是一种复杂的疾病，影响着全球越来越多的人。不幸的是，现有的治疗方法仅部分有效，且常常会引发严重的副作用。因此，利用病毒选择性地杀死癌细胞是一种新的、有前景的治疗方法。最近，水泡性口炎病毒（VSV）因其能够优先感染大多数人类肿瘤细胞而被用于溶瘤病毒疗法。然而，尽管有良好的溶瘤VSV突变体，但肿瘤细胞类型的巨大变异性以及它们逃避病毒感染的多种方式表明，为了有效治疗大多数癌症，有必要将各种病毒进行治疗性联合使用。更好地理解溶瘤病毒的感染机制和免疫系统募集对于开发安全有效的癌症治疗策略将具有重要价值。
